18-Sep-2026
Globe Newswire (Wed, 2-Sep 9:02 AM ET)
embecta to Participate in Investor Events
Globe Newswire (Mon, 31-Aug 5:00 PM ET)
Newsfile (Wed, 26-Aug 9:26 AM ET)
PRNewswire (Tue, 18-Aug 6:17 AM ET)
Business Wire (Mon, 17-Aug 2:18 PM ET)
EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
PRNewswire (Mon, 17-Aug 1:56 PM ET)
Globe Newswire (Mon, 17-Aug 10:39 AM ET)
Globe Newswire (Mon, 17-Aug 6:46 AM ET)
Embecta Corp. Sued for Securities Law Violations - FINAL DEADLINE TODAY - EMBC
PRNewswire (Mon, 17-Aug 2:26 AM ET)
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Embecta Corp. trades on the NASDAQ stock market under the symbol EMBC.
As of September 18, 2026, EMBC stock price climbed to $5.29 with 2,317,962 million shares trading.
EMBC has a beta of -0.31, meaning it tends to be less sensitive to market movements. EMBC has a correlation of 0.00 to the broad based SPY ETF.
EMBC has a market cap of $299.73 million. This is considered a Small Cap stock.
Last quarter Embecta Corp. reported $272 million in Revenue and $.56 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.30.
In the last 3 years, EMBC traded as high as $21.48 and as low as $2.77.
The top ETF exchange traded funds that EMBC belongs to (by Net Assets): VTI, IWM, VXF, IWN, FNDA.
EMBC has underperformed the market in the last year with a price return of -63.0% while the SPY ETF gained +16.8%. However, in the short term, EMBC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +70.4% vs +2.3% return in SPY. But in the last 2 weeks, EMBC shares have been beat by the market, returning -8.8% compared to an SPY return of -0.9%.
EMBC support price is $5.00 and resistance is $5.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EMBC shares will trade within this expected range on the day.